AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.…
Industry Peers
BiotechnologyKey Statistics
About Anavex Life Sciences (NASDAQ: AVXL)
›
Anavex Life Sciences (NASDAQ: AVXL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 34 employees.
The shares were at 0.5915 USD on 20 November 2026, down 91.9% over 52 weeks. Its 52-week range is 0.5901 USD to 7.600 USD, and it trades at the bottom of that range.
Its market capitalisation is 54.83M USD.
Anavex Life Sciences reports return on equity of -48.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 118.33M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 24 November 2026.